Company: CMND
Filing Date: 2025-11-26
Form Type: 424B5
Source: 0001213900-25-115106
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: 424B5
Chunk 0
---
Filed pursuant to Rule 424(b)(5)

Registration No. 333-275991

PROSPECTUS SUPPLEMENT

(To prospectus dated December 26, 2023)

<div align='center'>7,944,868 Common Shares

Pre-Funded Warrants to Purchase up to 2,865,960 Common Shares

CLEARMIND MEDICINE INC.</div>

We are offering pursuant to this prospectus supplement and the accompanying prospectus (i) 7,944,868 common shares, no par value, or the common shares, at an offering price of $0.12 per Common Share and (ii) pre-funded warrants to purchase up to 2,865,960 Common Shares at an offering price of $0.1199 per pre-funded warrant. Each registered pre-funded warrant will be exercisable for one Common Share at an exercise price of $0.0001 per Common Share, will be immediately exercisable, and will not expire until fully exercised. We are also offering pursuant to this prospectus supplement and the accompanying prospectus the Common Shares issuable upon the exercise of the pre-funded warrants.

Our Common Shares are currently traded on the Nasdaq Capital Market, or Nasdaq, under the symbol “CMND.” On November 25, 2025, the last reported sale price of our Common Shares on the Nasdaq was $0.16 per share.

Our Common Shares also trade on the Frankfurt Stock Exchange, or FSE, under the symbol “CWY”. On November 14, 2025, the last reported sales price of our Common Shares on the FSE was EUR 0.1613 (approximately $0.19) per share.

The highest aggregate market value of the outstanding Common Shares held by non-affiliates within the 60 days prior to this prospectus supplement based on the closing price of the Common Shares on the Nasdaq on November 25, 2025, as calculated in accordance with General Instruction I.B.5. of Form F-3, was approximately $38.3 million. During the twelve calendar months immediately prior to and including the date of this prospectus supplement, we sold securities with an aggregate market value of $4.35 million pursuant to General Instruction I.B.5. of Form F-3.

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, and have elected to comply with certain reduced public company reporting requirements.

Investing in the securities involves a high